In a blow to Bayer, a U.S. federal judge in Manhattan has said he will not block Johnson & Johnson’s survival claims on a key ...
Bayer argued that key claims in J&J’s marketing materials are rooted in flawed data, which could mislead doctors and patients ...
Bayer failed to persuade a federal judge to grant a preliminary injunction in its lawsuit accusing drugmaker Johnson & ...
Whippany-based Bayer is suing New Brunswick-headquartered Johnson & Johnson over claims the rival pharmaceutical company falsely advertised a competing prostate cancer drug. In a complaint filed Feb.
JNJ beats Q1 estimates and lifts guidance, but Stelara's patent loss looms. Can pipeline strength and new drugs sustain its growth momentum?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results